Antisecretory treatment: clear-cut benefit and potential risk
Proton pump inhibitors (PPI) remain a key element in the management of acid-dependent diseases. The antisecretory drug administration schedule should take into account the nature of the disease and the research data reflected in relevant international consensus. The patient’s adherence to the PPI in...
Main Authors: | S. I. Pimanov, E. V. Makarenko, E. A. Dikareva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2018-04-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/2450 |
Similar Items
-
The Effect of Esomeprazole 40 mg Single Therapy in Patients with Non-Erosive Reflux Disease Who Are Resistant to Standard-Dose Proton Pump Inhibitor Therapy: An Open-Label Multicenter Study
by: Jae Kyu Sung, et al.
Published: (2016-12-01) -
In Vitro and In Vivo Rat Model Assessments of the Effects of Vonoprazan on the Pharmacokinetics of Venlafaxine
by: Chen F, et al.
Published: (2020-11-01) -
Inadequate response to proton pump inhibitor therapy: Causes and patient management tactics
by: Iu V Evsiutina, et al.
Published: (2015-02-01) -
Efficacy of Seven-day High-dose Esomeprazole-based Triple Therapy versus Seven-day Standard Dose Non-esomeprazole-based Triple Therapy as the First-line Treatment of Patients with Helicobacter pylori Infection
by: Young Dal Lee, et al.
Published: (2020-09-01) -
Comparative evaluation of the efficiency of different therapy options for gastroesophageal reflux disease in children
by: N. V. Butorina, et al.
Published: (2016-03-01)